FY2025 EPS Estimates for AxoGen Lifted by Leerink Partnrs

AxoGen, Inc. (NASDAQ:AXGN - Free Report) - Equities research analysts at Leerink Partnrs boosted their FY2025 earnings per share (EPS) estimates for shares of AxoGen in a research report issued on Monday, March 31st. Leerink Partnrs analyst M. Kratky now forecasts that the medical equipment provider will post earnings per share of ($0.11) for the year, up from their prior estimate of ($0.12). The consensus estimate for AxoGen's current full-year earnings is ($0.29) per share. Leerink Partnrs also issued estimates for AxoGen's FY2026 earnings at $0.04 EPS, FY2028 earnings at $0.23 EPS and FY2029 earnings at $0.34 EPS.

Several other equities research analysts have also recently commented on AXGN. Lake Street Capital assumed coverage on shares of AxoGen in a research report on Monday, March 17th. They set a "buy" rating and a $30.00 price target on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $24.00 target price on shares of AxoGen in a report on Wednesday, March 5th. Finally, Canaccord Genuity Group raised their price target on AxoGen from $22.00 to $26.00 and gave the company a "buy" rating in a research note on Wednesday, February 26th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $22.60.

AxoGen Stock Down 3.7 %

Shares of AXGN traded down $0.65 during mid-day trading on Wednesday, hitting $17.04. 581,392 shares of the company's stock were exchanged, compared to its average volume of 425,102. The company has a 50-day simple moving average of $18.20 and a 200 day simple moving average of $15.95. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. The company has a market cap of $755.62 million, a PE ratio of -53.25 and a beta of 1.02. AxoGen has a 52 week low of $5.55 and a 52 week high of $21.00.

Remove Ads

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Intech Investment Management LLC bought a new stake in shares of AxoGen during the third quarter worth approximately $173,000. Charles Schwab Investment Management Inc. grew its holdings in AxoGen by 8.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 363,764 shares of the medical equipment provider's stock valued at $5,100,000 after buying an additional 28,659 shares in the last quarter. FMR LLC increased its position in AxoGen by 743.1% during the 3rd quarter. FMR LLC now owns 178,957 shares of the medical equipment provider's stock worth $2,509,000 after buying an additional 157,730 shares during the period. Quantbot Technologies LP bought a new stake in shares of AxoGen in the third quarter valued at about $165,000. Finally, BNP Paribas Financial Markets boosted its position in shares of AxoGen by 238.6% in the third quarter. BNP Paribas Financial Markets now owns 12,284 shares of the medical equipment provider's stock valued at $172,000 after acquiring an additional 8,656 shares during the period. Institutional investors and hedge funds own 80.29% of the company's stock.

Insider Activity at AxoGen

In other AxoGen news, Director Amy Mcbride Wendell sold 5,000 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $20.02, for a total transaction of $100,100.00. Following the completion of the sale, the director now owns 97,899 shares of the company's stock, valued at $1,959,937.98. This trade represents a 4.86 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Erick Wayne Devinney sold 15,111 shares of AxoGen stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $17.50, for a total transaction of $264,442.50. Following the transaction, the insider now directly owns 217,762 shares of the company's stock, valued at approximately $3,810,835. This trade represents a 6.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by company insiders.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.